Search Articles by Keyword

Found: 5 articles

Article Edition
A.V. Fateeva, E.V. Eliseeva, V.I. Apanasevich, A.A. Zaemskaya
Analysis of pharmacotherapy in patients with HR+HER2- metastatic breast cancer with PIK3CA mutations in real clinical practice 		№7 / 2024
Romashkina N.V., Klishina M.V., Carabina E.V.
Frequency and spectrum of PIK3CA mutations in hormone-dependent HER2-negative breast cancer: a single-center experience 		№4 / 2024
R.V. Orlova, M.I. Gluzman, A.A. Vakhitova
Possibilities of overcoming hormone resistance in patients with metastatic HR+ HER2- breast cancer using the drug alpelisib in various subgroups in real clinical practice 		№11 / 2023
V.F. Semiglazov, P.V. Krivorotko, A.V. Komyakhov, T.Yu. Semiglazova, L.P. Gigolaeva, T.T. Tabagua, M.D. Kazantseva, A.P. Tergoeva, D.G. Ulrikh, M.V. Chervyak, V.V. Klimenko, N.S. Amirov, E.K. Zhiltsova, V.V. Semiglazov
The role of alpelisib in the treatment of PIK3CA – a mutated breast cancer 		№11-12 / 2022
O.O. Gordeeva (1), I.P. Ganshina (1), V.I. Garifullina (2)
Dermatological toxity of alpelisib: clinical experience and review of current guidelines 		№7 / 2021

Бионика Медиа